LakeShore Biopharma receives Nasdaq delisting determination letter

Citius Oncology closes USD9m registered direct offering and concurrent private placement

Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes

Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth

Sanofi secures China approval for Tzield as first disease-modifying therapy for stage 2 type 1 diabetes

Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles

Atossa Therapeutics seeks Type C meeting with FDA to accelerate development of low-dose (Z)-endoxifen for breast cancer risk reduction

Phanes Therapeutics reports first BTC patient dosed in trial of spevatamig in combination with chemotherapy

Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis

Oncolytics reports strong efficacy signals for pelareorep in colorectal cancer

Anixa Biosciences completes dosing of fourth cohort in ovarian cancer CAR-T trial; Early results show promise

Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

Nuvalent presents zidesamtinib ARROS-1 clinical trial data for TKI Pre-treated patients with Advanced ROS1-positive NSCLC at WCLC 2025

IDEAYA Biosciences and Hengrui Pharma announce IDE849 (SHR-4849) positive Phase 1 data in small cell lung cancer at IASLC 2025 World Conference on Lung Cancer

Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor